Bruce Booth
@LifeSciVC
Followers
53K
Following
23K
Media
623
Statuses
12K
Early stage biotech VC. Recovering scientist. Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.
Cambridge, MA
Joined December 2010
Pfizer R&D has been great at discovering interesting assets and, upon portfolio prioritization changes, moving to out-licensing them… for other pharma to then value (TL1A at Telavant/Roche, IL6 with Tour/NVS, CNS with Cerevel/ABBV, desmoid with Springworks/MerckKGA). More than
12
6
112
"Speed Wins: The Focused-Team Formula for Platform Biotechs" - $KRRO CEO @ramaiyar shares his fun and creative thoughts on the challenge and opportunity of platform companies... a good read. https://t.co/t2Z9xIgkD7
lifescivc.com
By Ram Aiyar, CEO of Korro Bio, as part of the From The Trenches feature of LifeSciVC Let me tell you a secret that most biotech executives won’t admit at cocktail parties: we’re all making it up as...
2
5
21
Novartis acquires Tourmaline for $1.4B for pacibekitug, an IL-6 mAb. Fun fact: pacibekitug is yet another fully human mAb discovered from Medarex UltiMAb transgenic mouse platform. In 2004, Pfizer did a 10-year mAb discovery partnership with Medarex, which generated the
15
26
235
Who is ready for their next beach vacation? Book now!
0
0
0
Unfortunately there was a very high placebo response imagining all the things I could do with it … but I missed significance with only 1 matching number…
4
0
19
With a $1.8B exit value, I decided to invest. The 9,000,000x return would help my track record.
13
1
121
Atlas Venture raises $400M ‘opportunity’ fund, in sign of possible biotech rebound
statnews.com
Prominent biotech VC firm Atlas Venture has another $400 million to invest in drug companies.
2
7
46
😂😂
5
10
119
We are pleased to announce that the first subjects have been dosed in a Phase 1 trial evaluating our #NBD1 stabilizer in proprietary dual combinations with our complementary modulators in development for the treatment of cystic fibrosis. For details: https://t.co/L0dMPzAcB5
0
3
7
💯 very relatable. Dropped my three off this weekend… including my youngest… emotions of joy and sadness, excitement and anxiety, opportunity and loss… all mixed together. With waterworks 😭. Especially tough on the long solo drive back thinking about life hereafter 😳
Easily most resonant read of wk, from @drsam on his...big feelings...while preparing to drop off his daughter at college; as we just dropped off our middle daughter this wk as well, this post, incl...big feelings...was v relatable... @adamjshay
https://t.co/eJWwmzglpt
6
0
39
Fwiw, I’m not a fan of increasing the gov’ts role in business… this won’t likely end well…
5
2
22
Trump’s corporatism now involves the US demanding stakes in strategically important businesses that get any subsidies/grants… Intel likely only the first of many. The big Q to me is when will they demand ownership in biopharma… like Moderna for its mRNA platform. “We
12
4
48
"The Intelligent Entrepreneur: Real and Illusory Margins of Safety in Company Building" - reflections from @AnkitMahadevia on some of the key choices leadership teams have to make. https://t.co/7iXBjQEMIj
lifescivc.com
By Ankit Mahadevia, founder and board director of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotech leaders love talking about ‘margin of safety’—but what if the...
4
4
19
Very sad news… Jim Tobin passed away. After a productive scientific career at GI and Pfizer, Jim was a wonderful colleague at Atlas for a few years, and then a trusted partner at J&J’s Innovation Center. Strong scientist, great colleague, and good man… He will be missed. RIP.
10
2
60
Microsoft and Meta crushed earnings... adding ~$500B+ in market cap in pre-market trading. They've added more value in a single morning than the value of every Big Pharma except LLY. Or like adding 5 BMS's... 2.5 Merck's... or more than every publicly-traded biotech that has
13
7
97
SVB’s 2025 Healthcare Investments & Exits Report. VC fundraising is down... implications for future "dry powder" to support tomorrow's startups Biotech financings, down from peak, remain historically robust ($11B+ 1H25) China and AI, both top of mind
svb.com
Explore SVB’s 2025 Healthcare Investments & Exits Report, highlighting trends in venture capital fundraising, AI-driven healthtech growth, and biopharma shifts.
6
9
76
Excited to partner with @Novartis on a novel I&I program borne out of our targeted covalency engine at @matchpointtx Novartis inks deal with covalent medicines biotech Matchpoint for $60M upfront - https://t.co/AJMfDWFX5g
endpoints.news
Novartis partners with Matchpoint Therapeutics in $60M upfront deal for oral covalent inhibitors targeting inflammation, with potential payments up to $1B.
3
2
74
Big late stage win for Takeda! Oveporexton (TAK-861) hits on all endpoints in narcolepsy for the first-in-class orexin receptor 2 selective agonist. Congrats to Andy Plump and the team at $TAK - perseverance and conviction on the MoA paid off https://t.co/df8unSom4f
takeda.com
Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential...
9
15
109